Vitamin Pharmacogenomics: New Insight into Individual Differences in Diseases and Drug Responses

Hai-Yan He 3,*,a, Mou-Ze Liu 1,2,4,#,b, Yue-Li Zhang 1,2,4,c, Wei Zhang 1,2,4,*d

Abstract Vitamins are vital to sustain normal physiological function, metabolism, and growth for all living organisms. Being an integral component of coenzyme, vitamins can affect the catalytic activities of many enzymes and the expression of drug transporters. Genetic variations in metabolism and/or transporter genes of drugs can influence the exposure of the human body to drugs and/or their active metabolites, thus contributing to the variations in drug responses and toxicities. Nonetheless, pharmacogenomics studies on nutrients have been rarely summarized. In this article, we reviewed recent progress on vitamin pharmacogenomics, for a better understanding on the influence of vitamin-related gene polymorphisms on inter-individual differences in diseases and drug efficacy and safety.

Introduction

Pharmacogenomics (PGx), in a broad sense, refers to the study of DNA or RNA variations and their relationship with drug responses for better understanding of inter-individual differences in drug efficacy or safety. Examples include the association of genetic polymorphisms in the genes encoding the thiopurine methyltransferase (TPMT) with 6-mercaptopurine and azathioprine, genetic variation in the genes encoding cytochrome P450 2C9 (CYP2C9) and Vitamin K epoxide reductase complex subunit 1 (VKORC1) with warfarin [1,2], and genetic
Vitamin D binding protein (VDBP), vitamin D then can be transported to the liver and subsequently converted by 25-hydroxylase that is encoded by CYP27A1 into the prohormone calcidiol, which is also known as 25-hydroxycholecalciferol or 25-hydroxyvitamin D [25(OH)D] [16] (Figure 1). Vitamin D is usually present in several different forms, among which D$_2$ (ergocalciferol) and D$_3$ (cholecalciferol) are two major indispensible forms. Vitamin D$_2$ is mainly produced in natural plants, whereas vitamin D$_3$ is primarily synthesized from 7-dehydrocholesterol in the skin via sun exposure and converted by 1x-hydroxylase into the biologically-active calcitriol (1,25-dihydroxycholecalciferol or 1,25-dihydroxyvitamin D$_2$: 1,25(OH)$_2$D$_2$) in the kidney. About 95% of vitamin D in human body is produced in the skin through sunlight-dependent processes [17,18]. The regulation of vitamin D production process is strongly dependent on renal 1x -hydroxylase. Expression of renal 1x-hydroxylase can be up-regulated by parathyroid hormone (PTH) and inhibited by calcitriol itself. Then in the kidneys, both calcidiol and calcitriol will be converted by 24-hydroxylase into calcitroic acid, a water-soluble inactive compound, which is excreted into bile [16]. 1x-hydroxylase and 24-hydroxylase, which are encoded by CYP27B1 and CYP24A1 in humans, respectively, are of critical importance in governing calcitriol concentrations. It has been proposed that these two enzymes work jointly to regulate the concentration of calcitriol at the tissue level. Genetic polymorphisms in both CYP27B1 and CYP24A1 (Table 1) have been identified, which show significant association with the concentrations of vitamin D metabolites in circulation and with the risk of colorectal cancer [19,20]. Vitamin D deficiencies may lead to declined cognitive function, dementia, and Alzheimer’s disease [21]. Although the quantity of vitamins demanded is very small, they are indispensable for humans to maintain normal physiological functions. Vitamin deficiency would pose serious threat to human health. For example, the deficiency of vitamin A may lead to night blindness [12], whereas vitamin D deficiency may cause rickets [13]. However, vitamins can’t exert their functions in the human body without a variety of enzymes, transporters, receptors, and binding proteins that are involved in the absorption, distribution, metabolism, and excretion (ADME) of vitamins. If polymorphisms occur in the genes encoding the aforementioned proteins, the in vivo processing and the corresponding function of vitamins can become aberrant, thus affecting disease treatment [14]. Vitamins are roughly classified into two types, i.e., water-soluble vitamins and fat-soluble vitamins. The water-soluble vitamins do not require digestion, they can be directly absorbed in intestines and reach the required tissues via circulation. Fat-soluble vitamins can be dissolved in oil or fat. They are emulsified by the bile, absorbed in the small intestine, and delivered to different organs through lymphatic circulatory system.

Vitamin D

Vitamin D is one of the secoesteroid hormones, which can be obtained from diet or sun exposure to sunlight. It can be obtained by 25-hydroxylase to calcidiol in the liver, which is then converted to calcitriol by 1-hydroxylase in the kidney to become biologically active. Calcitriol subsequently reaches target cells through circulation and binds to vitamin D receptor and elicits the expression of vitamin D-responsive genes. On other hand, calcitriol can be catalyzed by 24-hydroxylase to become inactive initial catabolite 24, 25-dihydroxy D3.
Table 1  Effect of genetic polymorphisms on fat-soluble vitamins

| Vitamin | Gene | Protein function | Polymorphism | Effect of genetic polymorphisms on vitamins | Disease associated with vitamin deficiency | Refs. |
|---------|------|------------------|--------------|------------------------------------------|------------------------------------------|-------|
| D       | CYP27B1 | 1-Hydroxylase; key enzyme in generating the biologically-active calcitriol | rs28934604 (R107H) | Remarkably reduced activity in converting calcidiol to calcitriol (55% of wild type) | Calcium and phosphorus absorption barriers; declined cognitive function, dementia, and Alzheimer's disease | [19,20] |
|         | CYP24A1 | 24-Hydroxylase; key enzyme in transforming calcidiol and calcitriol into the inactive form | rs6068812 (L409S) |Remarkably reduced activity in catabolizing calcitriol (31% of wild type) | | |
|         | DBP | Vitamin D binding protein; the main transporter for calcitriol endocytosis | *10 and *11 | Protecting effect on patients with osteoporosis disease | | [24] |
|         | VDR | Vitamin D receptor | rs7968585 | Increased hazard ratios for composite outcome (incident hip fracture, myocardial infarction, cancer, and mortality over long-term follow-up) | | [25] |
| E       | APOA5 | Apolipoprotein A5; Participates in the transportation of lipoprotein | rs662799 (−1131T > C) | Higher vitamin E level | Reproductive disorders; muscle, liver, bone marrow and brain dysfunction; erythrocyte hemolysis | [31] |
|         | PAI-1 | Plasminogen activator inhibitor 1; Encodes a protein that functions as an inhibitor of fibrinolysis | 4G/5G |Benefiting more from vitamin E treatment for cardiovascular disease prevention | | [32] |
| K       | APOE | Apolipoprotein E; Transport and cellular uptake of lipoprotein | E3/4 and E4/4 |Significantly higher vitamin K1 levels | Easy bleeding, anemia, long blood coagulation time | [35,36] |

by Pani et al. that the variations in intron 8 (TAAA)n variable tandem repeats of DBP that encodes VDBP, the main transporter for calcitriol endocytosis, were significantly correlated with Graves' disease [23]. In a cross-sectional study including 56 men with idiopathic osteoporosis as well as 114 healthy controls, Al-oanzi et al. investigated variations in (TAAA)n-Alu of DBP. They found that DBP-Alu*10 and *11 alleles showed protection effect on patients with osteoporosis disease (OR = 0.39 and OR = 0.09, respectively). Carriers with 19–20 repeats (genotype 9/10, 9/11, and 10/10) had higher concentration of vitamin K1 levels [30].

Vitamin E

The fat-soluble vitamin E is known to be made up from tocopherols and tocotrienols. Vitamin E has prevention effects on the oxidation of phospholipids and polyunsaturated fatty acids, helps to maintain integrity of cell membrane, reduces blood lipid peroxide, prevents platelet aggregation, increases the stability of erythrocyte membrane, promotes the synthesis of red blood cells, etc. [26]. Previous studies have discovered that α-tocopherol (α-T) is one of the most biologically active forms of vitamin E and a lipid-soluble antioxidant [9,27]. After hepatic uptake, α-T can be rescreted by α-T transfer protein (α-TTP) from liver to plasma [28]. The genetic polymorphism of α-TTP can affect functions of vitamin E.

The transportation of vitamin E relies on triglyceride-rich lipoprotein (TRL) in vivo. Its tissue distribution may be driven by lipoproteins: low density lipoprotein (LDL) transfers vitamin E to tissues, whereas high-density lipoprotein (HDL) participates in reversing the transportation of vitamin E, i.e., transferring it from tissues back into the liver [29]. Apolipoprotein A5, which is encoded by APOA5, plays an important role in regulating the plasma triglyceride levels. Polymorphism in APOA5 is significantly associated with triglyceride (TG) concentration in the plasma, suggesting that vitamin E transportation may be regulated by APOA5 in vivo [30]. In type 2 diabetes patients with APOA5 1131T>C heterozygous mutation, the vitamin E level was about 13% higher than normal population. The probability of patients with higher vitamin E levels in TC genotype was about 2.6 times of that in normal population [30,31].

Vitamin E can effectively lower the levels of plasminogen activator inhibitor 1 (PAI-1), an inhibitor of fibrinolysis.
PAI-1 is encoded by SERPINE1 in humans and known as one of the risk factors to the cardiovascular diseases. The expression of PAI-1 can be influenced by 4G/5G polymorphism of SERPINE1 [32]. For a cohort containing 93 type II diabetic patients that were given a daily dose of 500 IU vitamin E for 10 consecutive weeks, Testa et al. found that, PAI-1 expression levels began to drop from the 10th week in patients carrying 4G/4G or 4G/5G genotype, while PAI-1 expression levels began to drop from the 5th week in patients with 5G/5G genotype (P < 0.01). These findings indicated patients with 5G/5G genotype may benefit more from vitamin E treatment for cardiovascular disease prevention [32].

**Vitamin K**

Vitamin K is also called the clotting vitamin, because it can promote blood clotting. Additionally, it also is involved in anticalcification, anticancer, bone formation, and insulin sensitization [33]. Vitamin K is known to be significantly related with the bone mineral density of elderly people [34]. There are two major forms of vitamin K: vitamin K1 and vitamin K2, with the former synthesized by natural plants and the latter by microorganisms. Human intestinal bacteria can also synthesize vitamin K2. The vitamin K intestinal absorption process includes bile-dependent solubilization, uptake into the enterocytes, packaging, and exocytosis to the lymphatic system, which is similar to that for the lipids.

*APOE* genetic polymorphisms are known to affect transportation and cellular uptake of lipoprotein. Plasma vitamin K level in hemodialysis patients was found to be correlated with the genotype of *APOE* (order E2 > E3 > E4) [35]. In another study on Chinese and UK healthy elders, researchers found that the vitamin K1 level in individuals with E4/E4 or E3/4 genotype was significantly higher than those with E3/3 or E2/3 genotype, while the percentage of undercarboxylated osteocalcin (ucOC, total osteocalcin adjusted) was lower in APOE 4 allele carriers than people with other genotypes in Chinese [36]. Kohlmeier et al. reported that *APOE* genotype could influence vitamin K levels in the blood, which might be a significant determinant of bone fracture [34].

The vitamin K-epoxide cycle is very important to the function of vitamin K and its storage in the microsomal cells. Two major integral membrane proteins participate in the process: γ-glutamyl carboxylase (GGCX) and vitamin K epoxide reductase (VKOR, both of which are suggested to be involved in reduction and oxidation of membrane-bound vitamin K [37]. Polymorphisms in VKORC1 and GGCX can influence the vitamin K recycle in liver, which might hold true in the extrahepatic tissues as well [38]. There is evidence suggesting that common polymorphisms of genes involved in vitamin K metabolism (e.g., *APOE* and *VKOR*) might lead to abnormal levels of vitamin K, making dose adjustment necessary. However, the observed genetic effects need to be validated by case-control studies with large sample sizes.

**Vitamin B12**

Vitamin B12, also known as cobalamin due to the inclusion of cobalt, is the only vitamin that contains metal element. Vitamin B12 can be synthesized by intestinal microorganisms or obtained from diet. Three key proteins, haptocorrin (HC), intrinsic factor (IF), and transcobalamin II (TCII), are responsible for the pharmacokinetic absorption and cellular uptake of vitamin B12 [39]. Vitamin B12 participates in erythrocyte formation and DNA synthesis. Therefore, long-term inadequate intake of vitamin B12 may eventually lead to hematological disorders or other clinical disorders such as body immune deficiency, megaloblastic anemia, coronary heart disease, gastrointestinal, and nervous system diseases [40]. Studies in Indian population have reported that a low level of vitamin B12 was related to a higher risk of coronary artery disease [41,42].

In recent years, identification of diseases-related SNPs has been greatly facilitated by the application of high-density genotyping arrays and genome-wide association studies (GWAS). Some SNPs that are reported to influence vitamin B12 levels have been identified. For instance, SNP 772G > A (rs602662) in the exon 2 of the gene encoding fucosyl transferase (FUT2) was related with the alterations in plasma vitamin B12 levels [43]. Notably, rs602662 has been repeatedly identified by GWAS analyses. Compared to individuals with AA or GA genotypes, individuals with GG genotype possessed the lowest levels of vitamin B12 (median; 175.3, 152.7, and 149.5 pM for AA, GA and GG, respectively). Furthermore, vegetarians with GG phenotype had a significantly lower plasma vitamin B12 level than non-vegetarians with AA genotype (140.7 pM vs. 174.2 pM) [44].

Vitamin B12 exists in the form of methylcobalamin and acts as a coenzyme of methionine synthase that catalyzes the methyl group transfer from 5-methyl-tetrahydrofolate. Polymorphisms in genes encoding transfer proteins of vitamin B12 may influence the cellular uptake process of vitamin B12 complex. Among them, 776C > G (rs1801198) in the gene encoding transcobalamin (TCN2), which leads to the substitution of arginine with proline, is the most common polymorphism [45]. This polymorphism may affect the binding affinity of TC to vitamin B12 and its ability of transporting vitamin B12 into tissues (Table 2). Individuals with TCN2 776GG genotype had significantly lower levels of HC—vitamin B12 complex, lower percentage of total transcobalamin—vitamin B12, but higher concentration of plasma methylmalonic acid (MMA). These findings suggest that the TCN2 776C > G polymorphism may influence the availability of vitamin B12, thus leading to a low vitamin B12 status. In a cohort containing 359 young healthy non-pregnant women, Von et al. reported significantly lower levels of transcobalamin-vitamin B12 complex in the plasma of individuals with 776GG genotype than those with 776CC genotype (74 vs. 87 pM; P = 0.02), suggesting less vitamin B12 available for cellular uptake and metabolism in the former individuals [45]. Future investigations are needed to verify whether there would be functional effects on diseases when the TCN2 776C > G polymorphism is coupled with inadequate dietary vitamin B12 intake.

**Vitamin C**

Vitamin C is a water-soluble vitamin, also known as L-ascorbic acid, which is a very important scavenger for the endogenous free radical and can be neuroprotective by reducing damages from excitotoxicity [9]. The main function of
Table 2  Effect of genetic polymorphisms on water-soluble vitamins

| Vitamin | Gene       | Protein function                                                                 | Polymorphism | Effect of genetic polymorphisms on vitamins                                                                 | Disease associated with vitamin deficiency or excess                                                                 | Ref. |
|---------|------------|-----------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------|
| B12     | FUT2       | Fucosyl transferase; transporter required for cellular uptake of B12             | rs602662 (772G>A) | Low concentrations of cellular and plasma vitamin B12 in G allele carriers                                    | Deficiency: pernicious anemia                                                                                           | [44] |
| TCN2    |            | Transcobalamin II; transfer protein of vitamin B12                               | rs1801198 (776C>G) | Significantly lower levels of haptocorrin–vitamin B12 complex, lower percentage of total transcobalamin–vitamin B12 in GG allele carriers |                                                                                                                                 | [45] |
| C       | SVCT2      | Sodium-dependent vitamin C transporters; transporter responsible for intake and discharge of ascorbic acid to maintain the homeostasis of vitamin C | rs613951     | Higher risk of acute coronary syndrome when taking lower median dietary vitamin C in TT allele carriers         | Deficiency: scurvy and skin purpura; gum bleeding Excess: urinary stones                                                | [47] |
|         | (SLC23A2)  |                                                                                    | rs1776964    | More vitamin C absorption in TT allele carriers than carriers of CC genotype.                                      |                                                                                                                                 |      |
| Folic acid | MTHFR    | Methylenetetrahydrofolate reductase; major enzyme for folic acid metabolism     | rs1801133 (677C>T) | Higher risk of cardiovascular diseases in TT allele carriers than C allele carriers                             | Deficiency: giant young red blood cell anemia, leukopenia                                                               | [52] |
| SLC19A1 | RFC-1      | Solute carrier family 19 member 1; transporting folic acid across the placenta and the blood–brain barrier | rs1051266 (80A>G) | Higher risk to have Down syndrome children in GG allele carriers                                             |                                                                                                                                 |      |

Vitamin C is to help human body to accomplish the REDOX reaction, thus important in preventing diseases, such as cancer, atherosclerosis, and rheumatism, as well as in enhancing immunity. Vitamin C has been considered to have no harm, since the kidney can drain off excessive vitamin C. It should be noted that vitamin C is essential to many biosynthetic processes that sufficient uptake is required for everybody. For example, vitamin C can improve endothelial function that is involved in cardio protection and collagen synthesis. Deficiency of vitamin C may lead to decreased collagen in atherosclerotic plaques, thus causing plaque rupture, blood clots, and even death in severe cases [46].

Sodium-dependent vitamin C transporters (SVCTs) are responsible for intake and discharge of ascorbic acid to maintain the homeostasis of vitamin C in vivo. Among them, SVCT2 functions to ensure the intracellular accumulation of ascorbic acid against the concentration gradients in the aorta or other active metabolism tissues [47]. The intronic SNP rs6139591 C > T in SVCT2 (also known as SLC23A2) (Table 2) is associated with the alterations in intake of vitamin C and concentration of circulating ascorbic acid. A large-scale clinical cohort study involving 57,053 cases followed-up for 6.4 years reported that the absorption of vitamin C from food is less in the female patients carrying rs6139591 TT genotypes. These patients had a higher risk (increased 5.39-fold) of acute coronary syndrome than patients carrying rs6139591 CC genotypes [47]. In addition, women with homozygous rs1776964 TT genotypes of SVCT2 can absorb more vitamin C than carriers of CC genotype. These results indicate that polymorphisms of the SVCT2 gene may be related to risk of acute coronary syndrome in females [46,47]. Therefore, vitamin C supplement may be effective for preventing acute coronary syndrome in females.

**Folic acid**

Folate or folic acid (FA) belongs to vitamin B9, which is water-soluble and can be obtained from natural food or dietary supplements. FA, as well as the cobalamin and pyridoxine, is one of the key cofactors in homocysteine cycle, which are crucial for the synthesis of norepinepherine, creatine, melatonin, and even DNA [48]. Folate is also important in protein biosynthesis and central to cell viability.

Methylenetetrahydrofolate reductase (MTHFR) is the major enzyme for folic acid metabolism in vivo. Meta-analysis on genetic polymorphism 677C>T in MTHFR showed that people with TT genotype have a higher risk (CI: 14%–21%) of suffering from cardiovascular diseases than C allele carriers [49]. In addition, Torre et al. have found that MTHFR 677C>T polymorphism can influence the occurrence (P = 0.037) of colorectal cancer in a folic acid-dependent manner. Patients with MTHFR 677TT genotype have a higher risk of colorectal cancer (OR = 2.4) when their FA levels are low [50].

The protein reduced folate carrier (RFC-1), which is encoded by SLC19A1, participates in FA transportation across the placenta and the blood–brain barrier. FA deficiency can lead to abnormal DNA methylation profiles, which may ultimately lead to congenital disorders, cardiovascular diseases neuropsychiatric diseases or even cancer [51]. RFC-1 genetic
polymorphism 80A > G is reported to be related with a decreased FA level and some kind of congenital diseases such as ischemic heart disease [52]. Coppede et al. performed a meta-analysis involving 930 mothers with Down syndrome (DS) children [52] and showed that RFC-1 80GG genotype carriers had 1.27 times higher risk to have DS children, while the risk of having DS children was increased by about 1.14-fold in patients carrying a single G allele. This finding suggests that genetic polymorphism of RFC-1 may have effects on fetal neuronal development via regulating the transportation of FA.

**Challenges and perspectives**

Most of the studies up till now have demonstrated a potential link between SNPs and the absorption, transportation, metabolism and excretion processes of vitamins. However, the conclusions could be controversial under the clinical conditions. In the clinic, the nutritional status observed may change under disease status. Basic nutrition supplements can significantly improve patients’ functional outcomes and living standard. However, the typically-formulated standard nutritional replacement for patients contains only carbohydrates, proteins, and fats, but no vitamin or other minerals included. Some symptoms of disease would be exacerbated under the condition of vitamin deficiencies, which in turn would be a barrier for the body respond to many other drug therapies. In recent years, pharmacogenomics studies on vitamins and other nutrition components have generated increasing interest due to their potential to be primary therapeutics. However, there still lacks strong evidence for gene–vitamin interactions. Many vitamin-related pharmacogenomics studies are flawed due to defects in experimental design, small sample size, or short observation period. Future studies are needed to confirm the pharmacogenomics effect of vitamins and their involvement in the related disease processes. Illustrating the exact mechanisms underlying the vitamin pharmacokinetics and pharmacodynamics will facilitate better understanding in variations of inter-individual drug responses. It is our hope that vitamin-related pharmacogenomics studies will yield more convincing data and will offer guidance for clinical applications in the coming precision medicine era.

**Competing interests**

The authors have declared no competing interests.

**Acknowledgments**

This study was supported by grants from the National Key Research and Development Program (Grant No. 2016YFC0905000), National High-tech R&D Program of China (863 Program; Grant No. 2012AA02A518), National Natural Scientific Foundation of China (Grant Nos. 81522048, 81573511, and 81273595) and the Innovation-driven Project of Central South University, China (Grant No. 2016CX024).

**References**

[1] Krishna KD, Shewade DG, Lorjot MA, Beaune P, Balachander J, Sai CR, et al. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Eur J Clin Pharmacol 2014;70:47–56.

[2] Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, et al. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer 2014;61:1055–62.

[3] UK Collaborative HIV Cohort Study Steering Committee. HLA B*5701 status, disease progression, and response to antiretroviral therapy. AIDS 2013;27:2587–92.

[4] Bartley AN, Washington MK, Ventura CR, Ismaila N, Colasacco C, Benson 3rd AB, et al. HER2 testing and clinical decision making in Gastroesophageal Adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am J Clin Pathol 2016;146:647–69.

[5] Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002;347:103–9.

[6] Silva-Alves MS, Secolin R, Carvalho BS, Yasuda CL, Bilevicius E, Alvim MK, et al. A Prediction algorithm for drug response in patients with mesial temporal lobe epilepsy based on clinical and genetic information. PLoS One 2017;12:e0169214.

[7] To SW, Chen JH, Wong KH, Chan KC, Tsang OT, Yim WC. HLA-B*5701 genetic screening among HIV-1-infected patients in Hong Kong: is this a practical approach in Han-Chinese? Int J STD AIDS 2013;24:50–2.

[8] Schnitzler M. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:1318; author reply 9.

[9] Vonder HC, Peterson TC, Martens KM, Hoane MR. Vitamins and nutrients as primary treatments in experimental brain injury: clinical implications for nutraceutical therapies. Brain Res 2016;1640:114–29.

[10] Miret JA, Munne-Bosch S. Plant amino acid-derived vitamins: biosynthesis and function. Amino Acids 2014;46:809–24.

[11] Bender DA. Do we really know vitamin and mineral requirements for infants and children? J R Soc Promot Health 2003;123:154–8.

[12] Wiseman EM, Bar-El Dadon S, Reifen R. The vicious cycle of vitamin A deficiency: a review. Crit Rev Food Sci Nutr 2016;

[13] DeLuca HF. Vitamin D: historical overview. Vitam Horm 2016;100:1–20.

[14] Vaiopoulou A, Gazouli M, Karikas GA. Pharmacogenomics: current applications and future prospects towards personalized therapeutics. J BUON 2013;18:570–8.

[15] Stokes CS, Lammert F. Vitamin D supplementation: less controversy, more guidance needed. F1000Res 2016;5:F1000 Faculty Rev-2017.

[16] Shahrokhzi SZ, Ghaffari F, Kazerouni F. Role of vitamin D in female reproduction. Clin Chim Acta 2016;455:33–8.

[17] Cline J. Calcium and vitamin d metabolism, deficiency, and excess. Top Companion Anim Med 2012;27:159–64.

[18] Davis CD, Milner JA. Nutrigenomics, vitamin D and cancer prevention. J Nutrigenet Nutrigenomics 2011;4:1–11.

[19] Jacobs ET, Van Pelt C, Forster RE, Zaidi W, Hibler EA, Galligan MA, et al. CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Cancer Res 2013;73:2563–73.

[20] McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009;29:111–32.

[21] Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology 2014;83:920–8.
[22] Rosen Y, Daich J, Soliman I, Brathwaite E, Shoefield Y. Vitamin D and autoimmunity. Scand J Rheumatol 2016;45:439–47.

[23] Pani MA, Regulla K, Segni M, Hofmann S, Hufner M, Pasquino AM, et al. A polymorphism within the vitamin D-binding protein gene is associated with Graves’ disease but not with Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2002;87:2564–7.

[24] Al-oanzi ZH, Tuck SP, Mastana SS, Summers GD, Cook DB, Francis RM, et al. Vitamin D-binding protein gene microsatellite polymorphism influences BMD and risk of fractures in men. Osteoporos Int 2008;19:951–60.

[25] Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 2012;308:1898–905.

[26] Rigotti A. Absorption, transport, and tissue delivery of vitamin E. Mol Aspects Med 2007;28:423–36.

[27] Peh HY, Tan WS, Liao W, Wong WS. Vitamin E therapy beyond cancer: Tocopherol versus tocotrienol. Pharmacol Ther 2016;162:152–69.

[28] Meier R, Tomizaki T, Schulze-Briese C, Baumann U, Stocker A. Carotenoids and alpha-tocopherol among lipoproteins do not change when human plasma is incubated in vitro. J Nutr 1995;125:2610–7.

[29] Guardiola M, Ribalta J, Gomez-Coronado D, Lasuncion MA, de Oya M, Garces C. The apolipoprotein A5 (APOA5) gene predisposes Caucasian children to elevated triglycerides and vitamin E (Four Provinces Study). Atherosclerosis 2010;212:543–7.

[30] Hsu LA, Ko YL, Chang CJ, Teng MS, Wu S, Hu CF. The molecular basis of vitamin E retention: structure of human alpha-tocopherol transfer protein. J Mol Biol 2003;331:725–34.

[31] Romanchik JE, Morel DW, Harrison EH. Distribution of carotenoids and alpha-tocopherol among lipoproteins do not change when human plasma is incubated in vitro. J Nutr 1995;125:2610–7.

[32] DiNicolaantonio JJ, Bhutra J, O’Keefe JJ. The health benefits of vitamin K. Open Heart 2015;2:e000300.

[33] Kohlmeier M, Saufe J, Schaefer K, Asmus G. Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int 1998;62:278–81.

[34] Pilkley RM, Morton AR, Boffa MB, Noordhof C, Day AG, Su Y, et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007;49:432–9.

[35] Yan L, Zhou B, Nigdkar S, Wang X, Bennett J, Prentice A. Effect of apolipoprotein E genotype on vitamin K status in healthy older adults from China and the UK. Br J Nutr 2005;94:956–61.

[36] Shearer MJ, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv Nutr 2012;3:182–95.

[37] Zuchinali P, Souza GC, Aliti G, Botton MR, Goldraich L, Santos KG, et al. Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in anti-coagulated patients. J Thromb Thrombolysis 2014;37:338–44.

[38] Seetharam B. Receptor-mediated endocytosis of cobalamin (vitamin B12). Ann Rev Nutr 1999;19:173–95.

[39] Brito A, Hertrampf E, Olivares M, Gaitan D, Sanchez H, Allen LH, et al. [Folate, vitamin B12 and human health]. Rev Med Chil 2012;140:1464–75.

[40] Castro R, Barroso M, Rocha M, Esse R, Ramos R, Rivasco P, et al. The TCN2 776C>G polymorphism correlates with vitamin B12(12) cellular delivery in healthy adult populations. Clin Biochem 2010;43:645–9.

[41] Mohanty PK, Kapoor S, Dubey AP, Pandey S, Shah R, Nayak HK, et al. Evaluation of C677T polymorphism of the methylenetetrahydrofolate reductase gene and its association with levels of serum homocysteine, folate, and vitamin B12 as maternal risk factors for Down syndrome. Indian J Hum Genet 2012;18:285–9.

[42] Tanaka T, Sheer P, Giusti B, Bandinelli S, Piras MG, Usala G, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet 2009;84:477–82.

[43] Tanwar VS, Chand MP, Kumar J, Garg G, Seth S, Kartihkeyan G, et al. Common variant in FUT2 gene is associated with levels of vitamin B(12) in Indian population. Gene 2013;515:224–8.

[44] von Castel-Dunwoody KM, Kauwel GP, Shelnutt KP, Vaughan JD, Griffin ER, Maneval DR, et al. Transcobalamin 776C>G polymorphism negatively affects vitamin B-12 metabolism. Am J Clin Nutr 2005;81:1436–41.

[45] Cahill LE, El-Sohemy A. Vitamin C transporter gene polymorphisms, dietary vitamin C and serum ascorbic acid. J Nutrigenet Nutrigenomics 2009;2:292–301.

[46] Dalgard C, Christiansen L, Vogel U, Dethlefsen C, Tjonneland A, Overvad K. Variation in the sodium-dependent vitamin C transporter 2 gene is associated with risk of acute coronary syndrome among women. PLoS One 2013;8:e70421.

[47] Meshkin B, Blum K. Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics. Drug Metab Lett 2007;1:55–60.

[48] McNulty H, Pentieva K, Hoey L, Strain J, Ward M. Nutrition throughout life: folate. Int J Vitam Nutr Res 2012;82:348–54.

[49] Torre ML, Russo GT, Ragone M, Giadalla A, De Menis E, Arnaldi G, et al. MTHFR C677T polymorphism, folate status and colon cancer risk in acromegalic patients. Pituitary 2014;17:257–66.

[50] Bull CF, Mayrhofer G, O’Callaghan NJ, Au AY, Pickett HA, Low GK, et al. Folate deficiency induces dysfunctional long and short telomeres; both states are associated with hypomethylation and DNA damage in human WL2-NS cells. Cancer Prev Res (Phila) 2014;7:128–38.

[51] Coppede F, Lorenzoni V, Migliore L. The reduced folate carrier (RFC-1) 80A>G polymorphism and maternal risk of having a child with Down syndrome: a meta-analysis. Nutrients 2013;5:2551–63.